136265-09-3

Basic information

• Product Name: (Z)-ethyl 3-(3-nitrophenyl)acrylate
• Synonyms: (Z)-ethyl 3-(3-nitrophenyl)acrylate
• CAS NO: 136265-09-3
• Molecular Weight: 221.213
• Mol File: 136265-09-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (Z)-ethyl 3-(3-nitrophenyl)acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-ethyl 3-(3-nitrophenyl)acrylate(136265-09-3)
• EPA Substance Registry System: (Z)-ethyl 3-(3-nitrophenyl)acrylate(136265-09-3)

Safety Data

• Hazardous Substances Data: 136265-09-3(Hazardous Substances Data)

Upstream product

• 99-61-6 3-nitro-benzaldehyde 
• 105-36-2 ethyl bromoacetate 
• 623-73-4 diazoacetic acid ethyl ester 
• 109-63-7 boron trifluoride diethyl etherate 
• 555-68-0 (E)-3-Nitrocinnamic acid 

Downstream Products

• 5676-61-9 (Z)-3-(3-nitrophenyl)acrylic acid 

Relevant articles and documents

Iron(IV)-Corrole Catalyzed Stereoselective Olefination of Aldehydes with Ethyl Diazoacetate

Iron(IV)-corrole complexes were first investigated as catalysts for olefination of aldehydes with ethyl diazoacetate in the presence of triphenylphosphine. Efficient olefination of aromatic aldehydes with high trans-selectivity was observed, showing iron corrole is a new kind of promising catalyst for olefination reaction. Transformation of the phosphazine to ylide by iron(IV) corrole was proved to be the key step in the present system.

Silver-Catalyzed Cross-Olefination of Donor and Acceptor Diazo Compounds: Use of N-Nosylhydrazones as Diazo Surrogate

The cross-olefination reaction of donor and acceptor diazo compounds was explored. The use of N-nosylhydrazones as diazo surrogates and the dependence on silver catalysis were crucial for the reaction development. A variety of (hetero)aryl N-nosylhydrazones and α-diazo esters, amides, and phosphonates were compatible, and the functionalized alkene products were afforded in good to high yields with moderate (Z)/(E) selectivities. The experimental and DFT calculation results suggest that the cross-selectivity is due to selective activation of the silver catalyst for donor diazo compounds.

Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia

α-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula STR1 wherein R2 is OR5 or R5a ; R3 and R5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R5a is H, alkyl, arylalkyl or aryl; R4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.